turn in Medical Technology

Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier

... or radiation treatment, some patients' tumors may turn on certain genes as a strategy by the tumor to ... chemotherapy or radiation, tumors will often turn on DNA repair genes such as RAD51 as an adaptive ... In pre-clinical models, PCI-24781 was able to turn off RAD51 (and other DNA repair genes), ...

ASGE Urges Patients to Seek a Qualified Endoscopist Before Undergoing a Colonoscopy for Colorectal Cancer

... ability to detect and remove polyps before they turn into cancer. Colonoscopy's effectiveness is ... potentially precancerous conditions before they turn into cancer. Colonoscopy is the only procedure ... and removal of lesions and polyps before they turn into cancer. New advances in endoscopic ...

Pivotal Clinical Data Published for the Only Laser Phototherapy Device Cleared by the FDA for Hair Growth

... LaserComb is hypothesized to increase the biological molecule ATP which in turn increases cellular metabolism and cellular activity. The hair follicle ... and capable of producing thick terminal hair. The enhanced environment in turn invigorates the hair follicle which produces healthier hair, prevents ...

ASGE and The Pancreatic Cancer Action Network Partner to Raise Awareness About Pancreatic Cancer

... substances into the small intestine. This can cause the skin and eyes to turn yellow (jaundice) and the stool to turn pale. It can also cause pain, weight loss, nausea, vomiting, and itchy ...

Positive Mosquito Count for West Nile Virus Lead DEP, Southeastern PA Counties to Ramp up Treatment Activities

... drains. Roof gutters can produce millions of mosquitoes each season. -- turn over plastic wading pools when not in use. Stagnant water in a wading pool becomes a place for mosquitoes to breed. -- turn over wheelbarrows and don't let water stagnate in birdbaths. Both provide ...

Orion Genomics Gains Exclusive Worldwide Rights to the IGF2 Gene for Colorectal Cancer Risk Testing Through Licensing Agreement With Johns Hopkins University

... DNA sequence of a gene, cancer associated epigenetic changes can either turn off or "silence" genes that normally suppress cancer, or can inappropriately turn on genes that can lead to malignant cellular activity. Researchers at The ...

Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack

... DNA, and the cell's plasma membrane. Damage to the cell's membrane may in turn cause the release of more inflammatory substances that may turn on apoptosis, or programmed cell death, involving a series of biochemical ...

Spectrum Pharmaceuticals Announces Presentation of SPI-1620 Data at the AACR-NCI-EORTC International Conference

... and transient increase in blood flow to tumors. Increased blood flow in turn led to an increase in drug delivery to tumors, which in turn enhanced the efficacy of the chemotherapeutic drugs. Proof-of-principle ...

Telik Announces Publication of Positive Phase 1 Results of a Multicenter Study of Ezatiostat Hydrochloride (TELINTRA(R), TLK199) Tablets In Patients With Myelodysplastic Syndrome

... novel mechanisms of action. TELINTRA has a novel mechanism of action that inhibits a target enzyme called glutathione S- transferase P1-1 which in turn facilitates the activation of JNK kinase, a key regulator of cellular growth and differentiation of blood. TELINTRA has been shown to stimulate ...

GAA Calls on Secretary Clinton to Speak Out Against Gender-Based Violence During Her Africa Trip

... sexual assault survivors are 15 years or younger at the time of their attack. In addition, 10% of boys worldwide are sexually abused before they turn 18. In some countries, up to 50% of school children report having been physically or sexually abused while at school. Violence against women ...

Lilly and New York City Mayor Michael R. Bloomberg Announce Lilly Agrees to be First Tenant of East River Science Park; Issue Urgent Call for Healthcare Reform that Protects Innovation and Jobs

... innovative medicines to patients. However, to protect this innovation, we are going to need healthcare reform that encourages innovation and in turn leads to breakthrough, life-saving medicines for patients. In this case, patients battling cancer are the focus." According to 2006 data, ...

MJFF's Rapid Response Innovation Awards Hit Mid-2009 With Over $1 Million Funded in High-Risk/High-Reward Approaches to Parkinson's Disease

... a drug already approved by the U.S. FDA to treat kidney disease, prevents brain deterioration in pre-clinical models of Parkinson's. The drug may turn on a protective gene called DJ-1 in the brain. Dr. Freed is studying 12 people with recently diagnosed PD to determine if the drug can increase DJ-1 ...

King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use

... triple-action composition of niacin and inactive ingredients. These ingredients can generate a temporary, unpleasant effect if orally over-consumed, turn dissolved tablets into a thick gelatinous mixture making it difficult to draw into a syringe, or produce a mild burning sensation in the nostrils ...

MADIT-CRT Trial Meets Primary Endpoint

... regarding our product performance, clinical outcomes, regulatory approval of our products, and our growth strategy. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections ...

Amicus Therapeutics Commences Phase 3 Trial Evaluating Amigal(TM) for the Treatment of Fabry Disease

... regarded as a representation by Amicus that any of its plans will be achieved. Any or all of the forward-looking statements in this press release may turn out to be wrong. They can be affected by inaccurate assumptions Amicus might make or by known or unknown risks and uncertainties. For example, with ...

Alfacell Provides Shareholder Update

... come into the cells and cause death of the cancer. Another major master controller gene known as nfkB is also known to be elevated when normal cells turn into mesothelioma cells, and high levels of this gene have been associated with resistance to chemotherapy. In order to investigate whether Onconase ...

Families of Spinal Muscular Atrophy Announces Latest Developments on Three SMA Drug Discovery Programs

... three years for our work on tetracycline derivatives as a potential treatment of SMA. These compounds are intended to correct SMN2 splicing and in turn increase SMN protein levels. Using funding from FSMA to generate the preliminary data for a grant application, Paratek has been awarded a ...

Proteolix Presents Phase 1b/2 Clinical Data for Carfilzomib in Advanced Solid Tumor Patients at the 2009 ASCO Annual Meeting

... treatment of solid tumor patients. The compound's unique characteristics enable the drug to be well tolerated with consecutive day dosing, which in turn appears to improve anti-cancer activity. Early results among patients with late-stage or metastatic solid tumors who have failed multiple prior ...

Boston Scientific Welcomes Results of Brain Aneurysm Clinical Trial

... things, statements regarding clinical trials, regulatory approvals, competitive offerings and product performance. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections ...

Boston Scientific Begins Clinical Trial for Next-Generation Nitinol Stent to Treat Iliac Artery Disease

... things, statements regarding clinical trials, regulatory approvals, competitive offerings and product performance. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections ...

SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(R) Stent System More Cost Effective Than Bypass Surgery in Patients With Complex Coronary Artery Disease

... things, statements regarding clinical trials, regulatory approvals, competitive offerings and product performance. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections ...

Study Confirms Effectiveness of Innovative Prism Glasses For Hemianopia Patients

... to the other side and alert patients to objects and obstacles not otherwise visible to them. Alerted to the existence of these objects, patients turn to look, or, if their brains are fully adapted (remapped), perceive quickly where the objects are and automatically avoid them without turning their ...

Boston Scientific Launches Third-Generation Platinum Chromium Drug-Eluting Stent

... things, statements regarding clinical trials, regulatory approvals, competitive offerings and product performance. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections ...

New MADIT II Clinical Data Analysis Shows Long-Term Survival Benefit for Implantable Defibrillator Therapy

... regarding our product performance, clinical outcomes, regulatory approval of our products, and our growth strategy. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections ...

Boston Scientific Data Show Real-World Survival Rates for Implantable Cardiac Device Patients Exceed Rates From Clinical Trials

... regarding clinical trials, scientific activities, product performance, competitive offerings and growth investment. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections ...

Journal of American College of Cardiology Article Reports Fewer Repeat Procedures With Boston Scientific's TAXUS(R) Liberte(R) Stent

... things, statements regarding clinical trials, regulatory approvals, competitive offerings and product performance. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections ...

Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine

... include, among other things, statements regarding clinical trials, regulatory approvals, and product performance. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections ...

Cystic Fibrosis - Orphan Drug Designation for Innovative Treatment Against Lung Infections by Axentis Pharma AG

... to the endobronchial sites of infection in cystic fibrosis patients. This may result in prolonged high local drug concentration in the lung, which in turn may lead to higher efficacy and may allow lower doses. Currently, the company is initiating Phase II clinical trials that will assess the ...

NHS National Innovation Centre Cites VNUS Closure(R) Procedure as Select Innovative Technology

... without a general anaesthetic or overnight stay," said Michael Branagan-Harris, UK Managing Director for VNUS Medical Technologies UK Ltd. "This in turn has enabled hospitals to save money by freeing up expensive resources such as operating theatres, ward beds and staff for more invasive procedures." ...

Clinical Data Reinforce Safety and Efficacy of Boston Scientific's Two Drug- Eluting Stent Platforms

... things, statements regarding clinical trials, regulatory approvals, competitive offerings and product performance. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections ...

SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(TM) Stents More Cost Effective Than Bypass Surgery in Many Patients With Complex Coronary Artery Disease

... things, statements regarding clinical trials, regulatory approvals, competitive offerings and product performance. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections ...

Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent

... regarded as a representation by Amicus that any of its plans will be achieved. Any or all of the forward-looking statements in this press release may turn out to be wrong. They can be affected by inaccurate assumptions Amicus might make or by known or unknown risks and uncertainties. For example, with ...

Anti-Aging Expo & Symposium Showcases in Charlotte on March 28th

... Care Decisions? CHARLOTTE, N.C., March 24 /PRNewswire/ -- For anyone interested in how to live a vibrant and healthy life at any age, or to turn around current health issues, the Charlotte Anti-Aging Expo & Symposium may have the answers right in your own backyard. The Charlotte ...

CDC Analysis Finds Unique Social and Behavior Intervention Helps Reduce MRSA Rates Up to 62% in Study Hospitals

... 'Positive Deviance' Efforts turn the Tide on Antibiotic-Resistant Infections PRINCETON, N.J., March 23 /PRNewswire-USNewswire/ -- The Robert Wood Johnson Foundation (RWJF) and ...

Cancer Research 'David' Hopes to Slay 'Cancer Goliath'

... a pre-treated serum injected into a particular large animal. The serum causes the animal's system to create an immune-stimulating antibody which in turn is injected into a special strain of mice that has naturally occurring breast cancer. (The injected pre-treated serum into the large animal appears ...

Metastatic Bone Disease Patients Can Walk in Lazarus' Footsteps

... cells gain access to the blood stream, reach the bone marrow, begin to multiply and then grow new blood vessels to obtain oxygen and food -- which in turn causes the cancer cells to grow more and spread. For the most part, the goal of treating bone tumors is not curative, but rather palliative by ...

New Study Published in the Journal of Drugs in Dermatology Finds DOT Microablative CO2 Laser Optimum for Skin Rejuvenation

... The energy is applied in a "fractional" way in which tiny columns of thermal damage are spaced so that tissue between each is spared, which in turn leads to a faster healing process. The technological advancements in the delivery system of DOT technology allow us to offer patients custom ...

Teva's Azilect Use Dramatically Increases in Second-Line Therapy for the Treatment of Parkinson's Disease

... results show that PCPs rely heavily on levodopa/carbidopa formulations for early treatment of Parkinson's disease whereas neurologists more often turn to non-ergotic dopamine agonists. This difference in treatment patterns indicates a growth opportunity for non-ergotic dopamine agonists among PCPs. ...

Drug Development Program Started Based on CAP(R) Human Cell Line

... CEO Dr Rainer Lichtenberger added: "CEVEC is excited about the strong scientific and commercial prospects of the Theraptech project. rhuAP will turn out to perfectly demonstrate the unique strengths of CEVEC's proprietary CAP(R) cell expression technology, in combination with the ...

Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe Disease

... regarded as a representation by Amicus that any of its plans will be achieved. Any or all of the forward-looking statements in this press release may turn out to be wrong. They can be affected by inaccurate assumptions Amicus might make or by known or unknown risks and uncertainties. For example, with ...